ASP Isotopes (ASPI) Corporate presentation summary

Strategic focus and market opportunities

• Aims to become a key supplier of enriched isotopes for medical, semiconductor, and nuclear energy markets, each representing multi-billion-dollar opportunities.

• Medical isotope market projected to grow from $5.1bn in 2022 to $11.4bn by 2032, driven by cancer prevalence and personalized medicine.

• Secured long-term supply contracts, including for Silicon-28 with a global semiconductor company, and multi-year Carbon-14 agreements.

• Quantum Leap Energy subsidiary targets uranium enrichment for next-generation nuclear fuels.

• Plans to spin out Quantum Leap Energy as a standalone public company.

Technology and operational milestones

• Utilizes proprietary Aerodynamic Separation Process and Quantum Enrichment technologies for isotope separation.

• Enrichment facilities are modular, scalable, cost-effective, and designed to produce zero waste.

• First Quantum Enrichment facility for Ytterbium-176 completed in 4Q 2024, with commercial production expected in Q1 2025.

• Silicon-28 enrichment plant completed in 2024, with supply to semiconductor industry starting 2024.

• Expansion plans include a new facility in Iceland leveraging low-cost renewable energy and favorable regulations.

Market dynamics and supply chain

• Global isotope supply is highly concentrated, with Russia producing 85% and the Netherlands 15%, creating significant supply risk.

• Severe shortages and supply gaps exist for key medical isotopes such as Ytterbium-176, Zinc-68, and Carbon-14.

• Semiconductor market demand for enriched Silicon-28 is rising, with applications in AI, quantum computing, and electronics.

• Nuclear energy sector faces urgent need for HALEU fuel for SMRs, with no current Western supplier.

• Quantum Enrichment technology may enable cost-competitive HALEU production and recycling of nuclear waste.